Last reviewed 2026-04-23 · How we verify

sIPV+bOPV

This vaccine combines inactivated poliovirus (sIPV) and oral poliovirus vaccine (bOPV) to provide immunity against poliomyelitis.

This vaccine combines inactivated poliovirus (sIPV) and oral poliovirus vaccine (bOPV) to provide immunity against poliomyelitis. Used for Prevention of poliomyelitis.

At a glance

Mechanism of action

The vaccine works by introducing inactivated poliovirus and oral poliovirus antigens to the body, stimulating an immune response and providing protection against poliovirus infection. This is achieved through the administration of the vaccine, which triggers the production of antibodies and immune cells that can recognize and neutralize the poliovirus.

Approved indications

• Prevention of poliomyelitis

Common side effects

• Pain, redness, or swelling at the injection site

Key clinical trials

• Study of Concomitant Administration of the sIPV and DTaP or MMR (PHASE4)
• A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vaccine (Vero Cell) and Live Attenuated Poliomyelitis Vaccine in Healthy 2-month-old Infants (PHASE3)
• Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV (PHASE3)
• Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants (PHASE4)
• To Evaluate the Immunogenicity and Safety of Sequential Immunization Schedules of Sabin IPV and bOPV (PHASE4)
• A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a "2+1"Sequential Schedule With bOPV in Infants (PHASE3)
• A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a '1+2' Sequential Schedule With bOPV in Infants (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.